Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYTK Cytokinetics	$40.43 +0.2%	$42.09	$32.74 ▼ $68.44	$4.82B	0.94	1.61 million shs	893,391 shs
GMAB Genmab A/S	$20.59 +0.2%	$20.47	$17.24 ▼ $30.41	$13.63B	1.07	1.05 million shs	715,774 shs
ITCI Intra-Cellular Therapies	$131.87	$131.16	$64.09 ▼ $131.98	$14.05B	0.69	1.46 million shs	N/A
TEVA Teva Pharmaceutical Industries	$14.88 +1.1%	$15.23	$12.47 ▼ $22.80	$16.87B	0.72	9.93 million shs	6.57 million shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYTK Cytokinetics	0.00%	+2.41%	-6.39%	-19.04%	-38.12%
GMAB Genmab A/S	0.00%	+2.74%	+3.47%	-1.01%	-26.86%
ITCI Intra-Cellular Therapies	0.00%	0.00%	+0.05%	+3.66%	+80.00%
TEVA Teva Pharmaceutical Industries	0.00%	+9.37%	-1.16%	-31.76%	+7.75%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CYTK Cytokinetics	4.1132 of 5 stars	4.5	2.0	0.0	4.6	2.6	0.8	0.0
GMAB Genmab A/S	4.4438 of 5 stars	4.3	5.0	0.0	0.0	3.5	0.0	3.1
ITCI Intra-Cellular Therapies	2.2649 of 5 stars	1.1	3.0	0.0	4.5	1.1	1.7	0.6
TEVA Teva Pharmaceutical Industries	3.1105 of 5 stars	3.4	5.0	0.8	0.0	2.9	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYTK Cytokinetics	2.94	Moderate Buy	$79.13	95.71% Upside
GMAB Genmab A/S	2.69	Moderate Buy	$39.17	90.22% Upside
ITCI Intra-Cellular Therapies	2.17	Hold	$109.70	-16.81% Downside
TEVA Teva Pharmaceutical Industries	2.86	Moderate Buy	$23.43	57.45% Upside

Current Analyst Ratings Breakdown

Latest CYTK, TEVA, ITCI, and GMAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/24/2025	CYTK Cytokinetics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$55.00
4/21/2025	CYTK Cytokinetics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$120.00 ➝ $120.00
4/15/2025	CYTK Cytokinetics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$62.00 ➝ $54.00
4/15/2025	CYTK Cytokinetics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$120.00 ➝ $120.00
4/10/2025	CYTK Cytokinetics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$78.00 ➝ $78.00
4/9/2025	GMAB Genmab A/S	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $37.00
4/8/2025	CYTK Cytokinetics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00 ➝ $72.00
4/4/2025	CYTK Cytokinetics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$120.00 ➝ $120.00
4/2/2025	ITCI Intra-Cellular Therapies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$132.00 ➝ $132.00
4/1/2025	GMAB Genmab A/S	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform ➝ Underperform
3/11/2025	GMAB Genmab A/S	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $45.00

(Data available from 4/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYTK Cytokinetics	$18.47M	260.84	N/A	N/A	($3.94) per share	-10.26
GMAB Genmab A/S	$21.53B	0.63	$1.39 per share	14.80	$8.04 per share	2.56
ITCI Intra-Cellular Therapies	$680.50M	20.64	N/A	N/A	$6.15 per share	21.44
TEVA Teva Pharmaceutical Industries	$16.54B	1.02	$2.95 per share	5.05	$4.75 per share	3.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYTK Cytokinetics	-$526.24M	-$5.26	N/A	N/A	N/A	-17,906.25%	N/A	-50.21%	5/6/2025 (Estimated)
GMAB Genmab A/S	$1.14B	$1.74	11.83	11.57	2.65	36.30%	16.78%	13.79%	5/8/2025 (Estimated)
ITCI Intra-Cellular Therapies	-$139.67M	-$0.73	N/A	694.05	N/A	-14.07%	-9.93%	-8.38%	5/6/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.45	N/A	5.66	1.44	-9.91%	42.46%	6.65%	5/7/2025 (Estimated)

Latest CYTK, TEVA, ITCI, and GMAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	GMAB Genmab A/S	$0.26	N/A	N/A	N/A	$5.17 billion	N/A
5/7/2025	Q1 2025	TEVA Teva Pharmaceutical Industries	$0.47	N/A	N/A	N/A	$3.99 billion	N/A
5/6/2025	Q1 2025	CYTK Cytokinetics	-$1.41	N/A	N/A	N/A	$2.77 million	N/A
2/27/2025	Q4 2024	CYTK Cytokinetics	-$1.29	-$1.26	+$0.03	-$1.26	$14.26 million	$16.93 million
2/21/2025	Q4 2024	ITCI Intra-Cellular Therapies	-$0.08	-$0.16	-$0.08	-$0.16	$205.08 million	$199.22 million
2/12/2025	Q4 2024	GMAB Genmab A/S	$0.28	$0.57	+$0.29	$0.85	$884.02 million	N/A
1/29/2025	Q4 2024	TEVA Teva Pharmaceutical Industries	$0.69	$0.70	+$0.01	-$0.19	$4.10 billion	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
ITCI Intra-Cellular Therapies	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	$1.01	6.79%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYTK Cytokinetics	5.93	9.28	9.28
GMAB Genmab A/S	N/A	5.25	5.24
ITCI Intra-Cellular Therapies	N/A	7.66	7.51
TEVA Teva Pharmaceutical Industries	2.97	0.98	0.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYTK Cytokinetics	N/A
GMAB Genmab A/S	7.07%
ITCI Intra-Cellular Therapies	92.33%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
CYTK Cytokinetics	3.40%
GMAB Genmab A/S	1.54%
ITCI Intra-Cellular Therapies	2.60%
TEVA Teva Pharmaceutical Industries	0.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYTK Cytokinetics	250	119.19 million	114.00 million	Optionable
GMAB Genmab A/S	1,660	661.97 million	651.58 million	Optionable
ITCI Intra-Cellular Therapies	560	106.52 million	103.56 million	Optionable
TEVA Teva Pharmaceutical Industries	36,800	1.13 billion	1.13 billion	Optionable

CYTK, TEVA, ITCI, and GMAB Headlines

Recent News About These Companies

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Barclays PLC

April 27 at 3:54 AM | marketbeat.com

Brokerages Set Teva Pharmaceutical Industries Limited (NYSE:TEVA) Target Price at $23.43

April 26 at 1:45 AM | americanbankingnews.com

RBF Capital LLC Sells 40,000 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 25 at 6:42 AM | marketbeat.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Given Consensus Recommendation of "Moderate Buy" by Analysts

April 25 at 4:26 AM | marketbeat.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Purchased by BlackBarn Capital Partners LP